Explore
Validate
LearnPAB10135
antibody from Abnova Corporation
Targeting: MTOR
FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PAB10135 - Provider product page
- Provider
- Abnova Corporation
- Proper citation
- Abnova Corporation Cat#PAB10135, RRID:AB_1675312
- Product name
- MTOR polyclonal antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant protein corresponding to human FRAP1.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Vial size
- 100 μg
- Storage
- Store at -20°C.Aliquot to avoid repeated freezing and thawing.
Submitted references mTOR, translational control and human disease.
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
Tee AR, Blenis J
Seminars in cell & developmental biology 2005 Feb;16(1):29-37
Seminars in cell & developmental biology 2005 Feb;16(1):29-37
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM
Science (New York, N.Y.) 2005 Feb 18;307(5712):1098-101
Science (New York, N.Y.) 2005 Feb 18;307(5712):1098-101
Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC
Circulation 2004 Mar 16;109(10):1299-306
Circulation 2004 Mar 16;109(10):1299-306
No comments: Submit comment
Supportive validation
- Submitted by
- Abnova Corporation (provider)
- Main image
- Experimental details
- Western blot analysis using MTOR polyclonal antibody (Cat # PAB10135) on MCF-7/6 cell lysates. Antibody used at1 ug/mL .
